University College London Hospitals NHS
NHS Foundation Trust

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
March 2018

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below, a summary of performance submitted by UCLH in Quarter 3 (2017/18) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of December 2017.

For Further information on PID reporting, please visit the NIHR pages at:
http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm

University College London Hospitals NHS
NHS Foundation Trust

Initiating Clinical Research – HRA Approval

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Date of First Patient Recruited	Benchmark Met	Reasons for Delay
1	17/LO/0640	204303	Efficacy & Safety of UX007 in Movement Disorders associated to Glut1DS	20/10/2016	04/04/2017	04/08/2017		25/08/2017		11/09/2017	28/11/2017	No	Sponsor
2	17/WM/0017	201600	(MifeMiso trial)	16/02/2017	11/04/2017	06/04/2017		27/06/2017		06/07/2017	13/10/2017	No	Sponsor
3	17/LO/0475	220177	CABRIO proof of concept study V1.1 020217		12/04/2017	12/04/2017		18/05/2017		25/05/2017	24/08/2017	No	Sponsor
4	17/NE/0115	218417	MA39189 Trial Of Pirfenidone in Patients with Fibrosing uILD	16/01/2017	17/04/2017	26/05/2017		23/06/2017		14/07/2017	03/01/2018	No	Neither
5	17/EE/0128	222308	GEN-GCT	06/02/2017	24/04/2017	19/05/2017		07/08/2017		09/08/2017		No	Sponsor
6	17/SC/0185	214076	BGB-3111-302	10/11/2016	25/04/2017			28/07/2017		08/08/2017	22/08/2017	No	Sponsor
7	17/LO/0440	217506	A Phase 1 Study to Evaluate ISIS 814907 in Mild Alzheimer's Disease	26/04/2017	26/04/2017	20/06/2017		21/07/2017		25/07/2017	23/08/2017	No	Sponsor
8	16/WM/0472	211270	CONFIRM	26/04/2017	05/05/2017	14/03/2017		07/06/2017		01/08/2017		No	Neither
9	17/WM/0106	201079	MRI for early response prediction to anti-TNF therapy	27/01/2017	08/05/2017	28/04/2017		02/06/2017		13/06/2017	30/08/2017	No	Sponsor
10	17/EM/0183	220783	Effect of Mepolizumab in severe bilateral nasal polyps	27/02/2017	11/05/2017			16/08/2017		23/08/2017	13/11/2017	No	Sponsor
11	17/EM/0155	206803	POINT	05/05/2017	15/05/2017			01/12/2017		05/12/2017		No	Neither
12	17/SC/0055	219468	Secukinumab treatment in Juvenile Idiopathic Arthritis	09/05/2017	16/05/2017	27/03/2017		25/09/2017		28/09/2017		No	Sponsor
13	16/EE/0546	210292	BEST3	16/05/2017	19/05/2017			24/08/2017		22/02/2018		No	Sponsor
14	17/LO/0736	225746	BMS CN002012 (0078-1422)	27/09/2016	22/05/2017			12/10/2017		12/10/2017	01/11/2017	No	Sponsor
15	17/EM/0152	216307	Astellas 2215-CL-0304	17/11/2016	24/05/2017			29/09/2017		29/09/2017	21/01/2018	No	Sponsor
16	17/LO/0741	216587	MOVES-PD	19/12/2016	24/05/2017			06/11/2017		07/12/2017		No	Sponsor

17	17/LO/0769	218626	Structured education group versus audio-visual information in IBS	12/05/2017	25/05/2017	12/05/2017		02/06/2017		02/06/2017	20/06/2017	Yes	
18	17/YH/0181	227102	TAK-659 for DLBCL patients after 2 prior lines of chemotherapy	21/04/2017	30/05/2017			25/08/2017		13/09/2017	25/09/2017	No	Sponsor
19	17/LO/0627	218496	VAL-1221	09/01/2017	01/06/2017	19/06/2017		03/10/2017		04/10/2017	08/11/2017	No	Sponsor
20	17/NW/0317	224142	Krio	30/03/2017	02/06/2017			14/08/2017		30/08/2017		No	Sponsor
21	17/LO/0494	224195	Bluebirdbio HGB-212	28/03/2017	08/06/2017	24/05/2017		28/06/2017		30/06/2017	02/08/2017	Yes	
22	17/NW/0228	222219	Phase 3 Carfilzomib Study in Patients With Relapsed/Refractory Myeloma	18/04/2017	08/06/2017			11/10/2017		11/10/2017	15/11/2017	No	Sponsor
23	17/NW/0312	211974	EORTC protocol 1317-STBSG	10/05/2017	09/06/2017			07/08/2017		09/08/2017	23/10/2017	No	Sponsor
24	17/NW/0330	222996	Agios AG120-C-005	26/07/2016	12/06/2017			02/11/2017		03/11/2017	14/03/2018	No	Sponsor
25	16/SC/0584	198941	SINAPPS2	12/06/2017	12/06/2017			31/08/2017		25/09/2017		No	Neither
26	16/LO/1495	207629	SPACE	15/03/2017	16/06/2017			27/07/2017		04/08/2017	05/10/2017	No	Sponsor
27	17/EE/0264	228153	POSEIDON	11/05/2017	16/06/2017			12/09/2017		18/09/2017	12/12/2017	No	Sponsor
28	17/YH/0076	208944	CALM-DIEM	25/08/2016	19/06/2017	18/05/2017		22/06/2017		21/07/2017		No	Sponsor
29	17/LO/0893	211137	Hu5F9-G4 (47NHL)	03/02/2017	29/06/2017							No	Sponsor
30	17/LO/0959	223644	LITTLE JOURNEY TRIAL	30/06/2017	01/07/2017	30/06/2017		06/07/2017		06/07/2017	14/07/2017	Yes	
31	14/LO/0187	143913	TAS-120	10/07/2017	04/07/2017			13/10/2017		06/11/2017		No	Sponsor
32	17/LO/0812	226255	Treatment with CD19/CD22 CAR redirected T cells for DLBCL- ALEXANDER	10/04/2017	06/07/2017			25/08/2017		05/09/2017	07/09/2017	Yes	
33	16/LO/2157	217001	An efficacy, safety and tolerability study of Fosmetpantotenate in PKAN	29/09/2016	10/07/2017	13/07/2017		23/10/2017		20/12/2017		No	Sponsor
34	17/LO/0506	220370	AMELIA	10/07/2017	12/07/2017	05/07/2017		20/09/2017		26/09/2017	25/01/2018	No	Neither
35	17/NW/0168	218752	CA209-744	10/02/2017	17/07/2017	01/06/2017		09/08/2017		11/08/2017	12/10/2017	No	Neither
36	17/LO/1019	223213	AFPc332T in Advanced HCC	09/02/2017	01/08/2017	15/09/2017		17/01/2018		05/02/2018		No	Neither

37	17/EE/0291	203703	Phase III trial- pembrolizumab or brentuximab vedotin- Hodgkin Lymphoma	15/06/2017	03/08/2017			13/12/2017		14/12/2017	07/02/2018	No	Sponsor
38	17/EM/0166	222665	AVAIL-T	05/05/2017	04/08/2017			07/08/2017		16/08/2017	27/11/2017	No	Neither
39	17/ES/0051	223060	NuCana PRO-105	08/06/2017	07/08/2017			28/09/2017		28/09/2017	26/10/2017	No	Sponsor
40	17/LO/0955	220437	MAKO medial unicompartmental knee arthroplasty	17/07/2017	08/08/2017	01/08/2017		15/08/2017		15/08/2017	24/11/2017	No	Sponsor
41	17/LO/0797	220423	ABRE Study	28/02/2017	08/08/2017	01/08/2017		16/11/2017		30/11/2017	19/02/2018	No	Sponsor
42	17/NE/0165	217768	MA30143	13/10/2016	09/08/2017			02/11/2017		06/11/2017	15/12/2017	No	Sponsor
43	16/EE/0357	206501	Opicapone in clinical practice (OPTIPARK)	24/10/2016	09/08/2017	31/10/2016						No	Sponsor
44	17/LO/1055	228923	Elective rituximab in TTP	06/06/2017	10/08/2017	01/08/2017		31/08/2017		01/09/2017	13/10/2017	Yes	
45	17/LO/1060	187783	SUBSoNIC	10/08/2017	15/08/2017			14/11/2017		23/11/2017		No	Neither
46	17/LO/1306	228268	REACH 3	27/07/2017	18/08/2017			06/02/2018		08/02/2018		No	Sponsor
47	17/LO/0618	223878	IMvigor 130	07/08/2017	18/08/2017			19/10/2017		09/11/2017	07/03/2018	No	Neither
48	17/LO/0117	217367	ALLCAR19	09/08/2017	23/08/2017			25/09/2017		28/09/2017	01/10/2017	Yes	
49	17/EE/0384	218262	RCT of Apatinib in Patients with Advanced or Metastatic Gastric Cancer (GC)	07/02/2017	04/09/2017							No	Sponsor
50	17/LO/0977	200797	ICEMAN		06/09/2017			12/09/2017		12/09/2017	24/11/2017	No	Sponsor
51	17/LO/0693	226490	Long-term safety of Everolimus in patients with TSC related seizures	27/06/2017	19/09/2017			25/09/2017		27/09/2017		No	Neither
52	16/LO/0994	204296	Study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783	25/08/2017	19/09/2017			19/02/2018		19/02/2018	08/03/2018	No	Sponsor
53	17/EE/0016	206408	A Randomised Control Trial of SEEG Electrode Placement methods	16/08/2017	25/09/2017			06/10/2017		06/10/2017	01/11/2017	Yes	

54	16/EM/0324	204032	Safety & Efficacy of suvorexant for treatment of insomnia in AD subjects	20/07/2017	25/09/2017			24/11/2017		24/11/2017	17/01/2018	No	Sponsor
55	17/ES/0107	231506	Single arm study of Safety and Efficacy of Coversin in adult aHUS	20/07/2017	26/09/2017	14/09/2017		12/12/2017		31/01/2018		No	Sponsor
56	17/LO/0024	212247	Eli Lilly JPCJ	30/08/2016	03/10/2017			03/10/2017		03/10/2017	31/10/2017	Yes	
57	17/EE/0303	228718	Effect of MIN-102 in Male Patients with Adrenomyeloneuropathy	23/06/2017	03/10/2017							No	Neither
58	17/LO/1043	226184	INCB24360:epacadostat in combination with pembrolizumab and azacitadine	14/02/2017	06/10/2017			25/10/2017		26/10/2017	21/11/2017	Yes	
59	17/LO/1656	229212	CO39722 IMspire 170	13/07/2017	09/10/2017	14/11/2017		19/12/2017		15/01/2018		No	Neither
60	17/SC/0369	218189	NEPTUNES	24/05/2017	17/10/2017	06/10/2017		31/10/2017		30/11/2017		No	Sponsor
61	17/LO/1000	223047	Cryoablation (8 seconds) for the Management of Barrett?s Oesophagus	10/10/2017	20/10/2017	10/10/2017		25/10/2017		10/11/2017	17/11/2017	Yes	
62	17/SW/0247	231651	NP39403-RO6870810 as monotherapy and in combination in advanced MM	21/09/2017	20/10/2017			22/01/2018		23/01/2018		No	Sponsor
63	17/NS/0065	219548	Physical Activity and Stoma Study	12/07/2017	31/10/2017			28/11/2017		28/11/2017		No	Neither
64	17/LO/1367	225049	MO29872: Atezolizumab compared with chemotherapy in NSCLC	25/05/2017	01/11/2017			02/11/2017		08/12/2017	06/03/2018	No	Neither
65	17/NS/0077	218279	BLAST OSA study version 01	09/08/2017	01/11/2017			17/11/2017		07/12/2017		No	Sponsor
66	17/EE/0376	232157	Anetumab ravtansine thorough ECG and drug interaction study with CYP3A4	31/07/2017	06/11/2017							No	Sponsor
67	17/LO/1896	233209	A Phase 1 study of ADCT-502 in patients with advanced solid tumours	22/09/2017	06/11/2017	24/10/2017						No	Sponsor

68	16/LO/1637	211258	First-in-human, trial of HuMax-AXL-ADC in patients with solid tumours	25/10/2017	07/11/2017							No	Sponsor
69	17/SC/0229	225742	OCTIMET OMO1	01/11/2017	07/11/2017			22/02/2018		23/02/2018	27/03/2018	No	Neither
70	17/NE/0234	228388	MK3475-629	24/07/2017	08/11/2017			17/11/2017		20/11/2017		No	Neither
71	17/LO/1458	204582	ASD-Probiotic V.3	22/08/2017	09/11/2017			17/11/2017		17/11/2017	17/01/2018	Yes	
72	17/LO/1502	232726	ISIS-443139-CS2 - Open label extension study	12/09/2017	09/11/2017	09/11/2017		23/11/2017		23/11/2017	05/12/2017	Yes	
73	17/LO/0948	222446	FABULAS	02/11/2017	13/11/2017			25/12/2017		28/12/2017	22/02/2018	No	Sponsor
74	17/EE/0370	233951	TNT009-01: SAFETY, TOLERABILITY AND ACTIVITY OF TNT009	23/08/2015	17/11/2017							No	Sponsor
75	17/NS/0018	223787	FUTURE Study	13/10/2017	17/11/2017	11/08/2017		05/03/2018		06/03/2018		No	NHS Provider
76	17/WS/0256	233393	BLU-667-1101	01/11/2017	30/11/2017							No	Sponsor
77	17/LO/1861	210692	NEOlung	15/08/2016	06/12/2017			22/01/2018		25/01/2018		No	Sponsor
78	17/LO/1920	235022	Cardinal (BIVV009-03)	31/10/2017	08/12/2017							No	Neither
79	17/LO/1921	236323	Cadenza (BIVV009-04)	31/10/2017	08/12/2017							No	Neither
80	17/NW/0193	216411	IntAct	26/04/2017	12/12/2017			18/12/2017		08/02/2018		No	Neither
81	17/LO/0038	182633	UKP3BEP Trial	08/03/2017	13/12/2017							No	Sponsor
82	17/LO/1900	235038	INCB 01158-203	23/10/2017	20/12/2017	21/12/2017		20/02/2018		20/02/2018	01/03/2018	No	Sponsor
83	17/SC/0605	234167	Starpharma CTX	05/01/2018	08/01/2018							No	Neither
84	17/LO/1273	216265	CA209-648 (CheckMate 648)	22/05/2017	10/01/2018			18/01/2018		18/01/2018		No	Neither
85	17/EE/0177	220722	BOSTON KCP-330-023	16/01/2018	29/03/2018							Within 70 Days	
86	17/LO/1846	227211	Digital Interventions in Neuro-Rehabilitation (DINR) - Phase 1	18/12/2017	17/01/2018	18/12/2017		26/01/2018		26/01/2018		No	Neither
87	17/LO/1509	232288	MS-STAT2	01/09/2017	18/01/2018	16/01/2018		01/02/2018		02/02/2018	29/03/2018	Yes	
88	17/LO/1929	233885	Pembrolizumab+epacadostat & EXTREME regimen 1st line Treat-R/M HNSCC	07/11/2017	18/01/2018			21/02/2018		27/02/2018		No	Neither

89	17/LO/1808	231108	ICON9	04/07/2017	19/01/2018	18/12/2017						No	Sponsor
90	17/YH/0289	231276	ACE-CL-110	02/01/2018	22/01/2018							Within 70 Days	
91	18/LO/0116	239646	Prexasertib in Recurrent Ovarian Cancer (JTJN)	02/01/2018	24/01/2018							Within 70 Days	
92	16/EM/0181	201126	TAMARIN	12/07/2017	26/01/2018			13/03/2018		13/03/2018		Within 70 Days	
93	18/SC/0028	235714	CC-92480 Plus Dexamethasone in Relapsed and Refractory Multiple Myeloma	17/01/2018	29/01/2018							Within 70 Days	
94	18/LO/0226	231912	PF-06647020	21/09/2017	31/01/2018							Within 70 Days	
95	17/LO/1433	226791	WATS3D to detect oesophageal high grade dysplasia and adenocarcinoma	29/04/2017	01/02/2018			23/02/2018		23/02/2018		Within 70 Days	
96	17/EE/0040	222216	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	11/09/2017	02/02/2018			15/02/2018		15/02/2018		Within 70 Days	
97	14/NW/1238	160200	AZD6738	31/01/2018	07/02/2018							Within 70 Days	
98	18/LO/0047	235607	ARTISAN-SNM 105-0050	23/01/2018	08/02/2018			22/02/2018		23/02/2018		Within 70 Days	
99	16/SC/0201	202977	Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients with Bilateral Idiopathic PD	07/09/2016	12/02/2018							Within 70 Days	
100	17/LO/1140	223446	K0-TIP-001	03/10/2017	14/02/2018							Within 70 Days	
101	17/EE/0368	213669	STRESS-L	01/09/2017	21/02/2018			19/03/2018		20/03/2018		Within 70 Days	
102	17/SS/0082	222441	First RESTART, now SoSTART	10/09/2016	21/02/2018							Within 70 Days	
103	17/WS/0147	184216	Precision Panc	06/12/2017	27/02/2018			01/03/2018		01/03/2018		Within 70 Days	

104	17/LO/2032	235018	Patients with Metastatic Castration-Resistant Prostate Cancer	27/02/2018	02/03/2018							Within 70 Days	
105	16/EE/0324	203951	PRO-DLI	12/09/2017	09/03/2018							Within 70 Days	
106	17/NI/0203	187583	Short pulse width DBS	08/01/2018	15/03/2018			23/03/2018		23/03/2018		Within 70 Days	
107	17/LO/1972	231646	RCT: Direct Superior Approach vs Posterior Approach THA	02/02/2018	21/03/2018			03/04/2018		29/03/2018		Within 70 Days	
108	17/EE/0518	236497	Interstim Amplitude study	06/10/2017	22/03/2018							Within 70 Days	
109	17/SC/0387	208972	mINivAN	20/09/2017	23/03/2018							Within 70 Days	
110	17/NE/0090	203556	SeluDex	01/02/2018	28/03/2018							Within 70 Days	

Delivering Clinical Research

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	3	3	Not Available / Not Agreed			10/04/2017	8	Recruitment Finished

2	14/SC/1340	151325	A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease	Number Agreed	7	7	Date Agreed	27/11/2015	10	21/04/2017	10	Recruitment Finished
3	13/EM/0373	15394	An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma	Number Agreed	3	3	Date Agreed	01/01/2015	1	25/04/2017	1	Recruitment Finished
4	15/LO/1441	186018	A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura	Number Agreed	18	18	Date Agreed	01/11/2017	18	29/04/2017	18	Recruitment Finished
5	15/EM/0454	184386	An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus	Number Agreed	24	24	Date Agreed	01/06/2016	24	04/05/2017	24	Recruitment Finished

6	16/LO/0334	193988	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	2	2	Date Agreed	01/05/2017	2	05/05/2017	2	Recruitment Finished
7	16/NE/0027	187317	A phase 3, multicenter, randomized, open-label study of avelumab (MSB0010718C) alone or in combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum resistant/refractory ovarian cancer	Number Agreed	3	3	Date Agreed	01/11/2016	23	15/05/2017	23	Recruitment Finished

8	15/LO/0443	172123	A PHASE 3, MULTICENTER,RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Number Agreed	6	6	Date Agreed	09/07/1905	5	15/05/2017	5	Recruitment Finished
9	14/LO/1597	158625	A Randomized, Double-Blind, Placebo-Controlled, Four-Arm,Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phospha	Number Agreed	5	5	Date Agreed	01/01/2016	12	18/05/2017	12	Recruitment Finished

10	15/WM/0457	195511	An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent	Number Agreed	5	5	Date Agreed	01/09/2016	7	18/05/2017	7	Recruitment Finished
11	16/LO/1450	202124	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors	Number Agreed	4	4	Date Agreed	30/06/2018	5	19/05/2017	5	Recruitment Finished
12	16/SW/0090	199970	Ustekinumab in Subjects with Radiographic Axial Spondyloarthritis	Number Agreed	3	3	Date Agreed	31/07/2017	1	30/05/2017	1	Withdrawn By Sponsor
13	16/SC/0341	204761	A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function	Number Agreed	3	3	Date Agreed	01/10/2017	2	02/06/2017	2	Recruitment Finished

14	16/LO/1612	201997	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)	Number Agreed	20	20	Not Available / Not Agreed			09/06/2017	17	Recruitment Finished
15	16/LO/0083	193141	A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus best supportive care versus best supportive care in adults who require regular red-blood cell transfusions due t	Number Agreed	3	3	Date Agreed	01/02/2018	5	10/06/2017	5	Recruitment Finished
16	15/LO/1670	188788	Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum-Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Number Agreed	12	12	Date Agreed	01/04/2017	2	21/06/2017	4	Recruitment Finished

17	15/SW/0220	182750	A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Axial Nonradiographic Spondyloarthritis	Number Agreed	3	3	Date Agreed	17/07/2017	1	02/07/2017	1	Withdrawn By Sponsor
18	16/NW/0379	200426	LY2801653 and LY3009806 - Advanced or Metastatic Biliary Tract Cancer	Number Agreed	8	8	Date Agreed	01/05/2017	4	03/07/2017	4	Recruitment Finished
19	16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Number Agreed	3	3	Not Available / Not Agreed			24/07/2017	1	Withdrawn By Sponsor
20	16/EM/0165	203281	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (CANC 5545)	Number Agreed	2	2	Date Agreed	22/03/2018	2	28/07/2017	2	Recruitment Finished

21	14/LO/2156	166004	A Phase 2 Proof of Concept (PoC), DoubleBlind, Randomised, Placebocontrolled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VSN16R for the treatment of spasticity in patients with Multiple Sclerosis.	Number Agreed	75	75	Not Available / Not Agreed			31/07/2017	81	Recruitment Finished
22	16/EE/0243	207331	A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study Of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease	Number Agreed	5	5	Date Agreed	31/03/2017	1	05/09/2017	1	Withdrawn By Sponsor
23	16/LO/1810	209789	UTX-TGR-304	Number Agreed	3	3	Date Agreed	30/05/2018	3	12/10/2017	0	Recruitment Finished
24	10/H1102/44	0	MCRN146 (AC-056C501)	Not Available / Not Agreed			Not Available / Not Agreed			19/10/2017	2	Recruitment Finished
25	16/LO/1436	205613	Potential Predictors of Disease Progression in aHUS Patients	Number Agreed	10	10	Date Agreed	30/06/2018	6	31/10/2017	6	Recruitment Finished
26	15/LO/1936	183134	CANC - 4615	Number Agreed	3	3	Date Agreed	31/05/2017	0	13/11/2017	2	Withdrawn By Sponsor
27	17/EM/0089	222705	BREAKOUT	Number Agreed	10	10	Date Agreed	28/02/2018	1	15/11/2017	1	Withdrawn By Sponsor
28	16/SS/0134	199690	STRO 4724	Number Agreed	1	1	Not Available / Not Agreed			17/11/2017	1	Withdrawn By Sponsor

29	16/LO/1960	199019	Dose finding study of Sarilumab in children with sJIA	Number Agreed	1	1	Not Available / Not Agreed			20/11/2017	0	Recruitment Finished
30	15/LO/1950	184545	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance II)	Number Agreed	10	10	Date Agreed	01/11/2017	11	30/11/2017	11	Recruitment Finished
31	17/SC/0033	218114	A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma	Number Agreed	2	2	Not Available / Not Agreed			01/01/2018	3	Recruitment Finished
32	16/SC/0566	213579	A MULTICENTRE CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHEMIC STROKE (MEDIS)	Number Agreed	10	10	Not Available / Not Agreed			12/01/2018	0	Withdrawn By Sponsor

33	17/LO/0640	204303	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)	Number Agreed	3	3	Date Agreed	31/12/2017	2	31/01/2018	2	Recruitment Finished
34	16/LO/0574	150998	Phase I/II, First in Human, Dose Escalation Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with Relapsed/Refractory B Cell Malignancies and Expansion Cohorts in Patients with Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma (ABC subtype) that have Progressed after at least 1 but not more than 3 Prior Lines of Therapy	Number Agreed	6	6	Not Available / Not Agreed			31/01/2018	3	Recruitment Finished

35	16/NE/0142	202233	A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer	Number Agreed	3	3	Not Available / Not Agreed			01/02/2018	6	Recruitment Finished
36	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Number Agreed	4	4	Not Available / Not Agreed			05/02/2018	3	Recruitment Finished
37	17/NW/0228	222219	A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma	Number Agreed	2	2	Date Agreed	30/04/2018	5	13/02/2018	5	Recruitment Finished

38	16/WM/0512	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or without anaemia)	Number Agreed	9	9	Not Available / Not Agreed			15/03/2018	1	Recruitment Finished
39	15/LO/0685	148762	A comparison of Glycosade® and Uncooked Cornstarch (UCCS) for the treatment of hepatic glycogen storage diseases (GSD)	Number Agreed	2	2	Date Agreed	Apr-16	3	31/03/2018	3	Recruitment Finished
40	17/NE/0201	218005	A Prospective Observational Study of Patients with Primary Mitochondrial Disease (SPIMM-300)	Number Agreed	8	8	Not Available / Not Agreed			31/01/2018	10	Recruitment Finished